Borisy Alexis 4

What Happened Alexis Borisy, a director of Parabilis Medicines, was granted a derivative equity award on June 9, 2026 covering 20,215 shares. The grant is reported at $0.00 per share (total reported value $0) and is an award/option-style grant rather than an open-market purchase or sale.

Key Details

• Transaction date: June 9, 2026; Form 4 filed June 11, 2026 (timely filing).
• Instrument: derivative award (option) for 20,215 shares; reported price $0.00; total reported value $0.
• Vesting: The shares underlying the option vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the issuer's next annual meeting of stockholders, subject to Borisy's continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction code: A = Award/Grant.

Context This is a compensation-related equity award to a director (not a market purchase or sale). Such grants are common to align director incentives with shareholders and do not by themselves indicate the insider’s intent to buy or sell stock. The award vests on a one-year cliff or sooner at the next annual meeting if conditions are met.